EE140 Estimated Costs for All-Cause Grade 3/4 Adverse Events Among First-Line Tyrosine Kinase Inhibitor Plus Immuno-Oncology-Based Combination Therapies for Patients with Advanced Renal Cell Carcinoma from the United States Perspective
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.390
https://www.valueinhealthjournal.com/article/S1098-3015(22)00591-5/fulltext
Title :
EE140 Estimated Costs for All-Cause Grade 3/4 Adverse Events Among First-Line Tyrosine Kinase Inhibitor Plus Immuno-Oncology-Based Combination Therapies for Patients with Advanced Renal Cell Carcinoma from the United States Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00591-5&doi=10.1016/j.jval.2022.04.390
First page :
Section Title :
Open access? :
No
Section Order :
10340